Sign in

CIK 0001672619 · Non-accelerated filer

Enliven Therapeutics, Inc.

Sign in to watch
Ticker
ELVN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
811523849
Phone
650-547-5814
Business address
205 PARK ROAD, BURLINGAME, CA, 94010
Former names
IMARA Inc.
  1. 4 Planned sale Chief Financial Officer sold 11,870 shares at an average $15.02 ($178,327)
  2. 4 Planned sale President and CEO sold 12,000 shares at $14.64 ($175,709)
  3. 4 Planned sale Chief Operating Officer sold 1,085 shares at an average $15.03 ($16,306)
  4. 4 Planned sale Chief Financial Officer sold 1,130 shares at an average $15.07 ($17,025)
  5. 4 Planned sale Chief Scientific Officer sold 6,566 shares at an average $13.07 ($85,790)
  6. 4 Open-market sale President and CEO sold 8,195 shares at an average $13.05 ($106,915)
  7. 4 Planned sale Director sold 216 shares at $13.00 ($2,808)
  8. 144 Insider Sale of Securities
  9. 144 Insider Sale of Securities
  10. 144 Insider Sale of Securities
  11. 4 Planned sale President and CEO sold 7,779 shares at $13.01 ($101,238)
  12. 4 Planned sale Chief Scientific Officer sold 8,888 shares at an average $13.01 ($115,646)
  13. 4 Planned sale Director sold 4,280 shares at an average $13.02 ($55,727)
  14. 144 Insider Sale of Securities
  15. 144 Insider Sale of Securities
  16. 10-Q Report Quarterly Report
  17. 8-K Event Results of operations
  18. 4 Planned sale Chief Scientific Officer sold 8,546 shares at $13.08 ($111,751)
  19. 4 Planned sale President and CEO sold 8,026 shares at $13.08 ($104,999)
  20. 4 Planned sale Chief Scientific Officer sold 12,000 shares at $13.62 ($163,498)

Page 25 of 40 · 798 filings